Where frailty meets diabetes
Authors:
- 26 January 2016
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 32 (S1) , 261-267
Abstract
Diabetes is a chronic illness that has an effect on multiple organ systems. Frailty is a state of increased vulnerability to stressors and a limited capacity to maintain homeostasis. It is a multidimensional concept and a dynamic condition that can improve or worsen over time. Frailty is either physical or psychological or a combination of these two components. Sarcopenia, which is the age‐related loss of skeletal muscle mass and strength, is the main attributor to the physical form of frailty. Although the pathophysiology of diabetes is commonly focused on impaired insulin secretion, overload of gluconeogenesis and insulin resistance, newer insights broaden this etiologic horizon. Immunologic factors that create a chronic state of low‐grade inflammation – ‘inflammaging’ – have an influence on both the ageing process and diabetes. Persons with diabetes mellitus already tend to have an accelerated ageing process that places them at greater risk for developing frailty at an earlier age. The development of frailty – and sarcopenia – is multifactorial and includes nutritional, physical and hormonal elements; these elements are interlinked with those of diabetes. A lower muscle mass will lead to poorer glycaemic control through lower muscle glucose uptake. This leads to higher insulin secretion and insulin resistance, which is the stepping stone for diabetes itself. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
This publication has 88 references indexed in Scilit:
- Diabetes and risk of physical disability in adults: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2013
- Diabetes and Aging: Epidemiologic OverviewClinics in Geriatric Medicine, 2008
- Update on Diabetes in the Elderly and the Application of Current TherapeuticsJournal of the American Medical Directors Association, 2007
- Elevated Glucose and Diabetes Promote Interleukin-12 Cytokine Gene Expression in Mouse MacrophagesEndocrinology, 2006
- Interleukin-15: a new cytokine target for the treatment of inflammatory diseasesCurrent Opinion in Pharmacology, 2004
- Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 DiabetesDiabetes Care, 2004
- Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and CareThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2004
- Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetesJournal of Molecular Medicine, 2003
- Low Production Capacity of Interleukin-10 Associates With the Metabolic Syndrome and Type 2 DiabetesDiabetes, 2002
- C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes MellitusJAMA, 2001